The 2 most recent market catalysts affecting $GNLX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
Genelux Says Frontiers In Oncology Published Case Report Of Platinum-Relapsed Small Cell Lung Cancer Patient Achieving 16.7 Months Progression-Free Survival And 84.6% Target Lesion Reduction After Olvi-Vec And Platinum Rechallenge
The headline presents highly positive clinical data for Genelux's Olvi-Vec in platinum-relapsed small cell lung cancer, a notoriously aggressive and difficult-to-treat disease. Ach…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate
Genelux (GNLX) announced its Q2 earnings, reporting a loss of $(0.21) per share, which significantly missed the analyst consensus estimate of $(0.19). This 10.53% miss, coupled wit…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.